leisure time -WSS

leisure time

author：explore 2025-09-28 21:05:10 - browse：8583

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

focus

WSS

My yearlong odyssey to get my son’s ADHD medication covered

The surgeon had a dilemma only a Nazi medical text could resolve

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Roche drug slashes death risk in early

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Questions loom on AstraZeneca cancer drug as safety concerns ebb

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

23andMe had bad news about my health. I wish a person had delivered it

Dewpoint Therapeutics lays off staff after losing partnerships

United colonoscopy coverage change 'may cost lives,' doctors say

eGenesis tests gene

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

STAT Summit: The economic case for universal basic health care

Continuity nursing helped my family in our darkest PICU moments

STAT Readout Newsletter: Biotech news today

ChatGPT in medicine: STAT answers readers' burning questions

How AI can help patients find reliable information about doctors

explore

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Elizabeth Holmes banned from government health programs

Why doctors need education on FDA device approval process

Biotech venture capitalists face new demands from investors

Health tech investors get more selective as pandemic boom fades

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

explore

Wikipedia

focus

explore